Question 1

What is SELLAS Life Sciences Group's P/E ratio?

Accepted Answer

SELLAS Life Sciences Group (SLS) P/E ratio is currently not available. When trailing twelve-month earnings are negative (a net loss), the P/E ratio is mathematically meaningless and is reported as not available (N/A). In that case investors typically use P/S, EV/Sales, or forward P/E instead.

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for SELLAS Life Sciences Group?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For SELLAS Life Sciences Group specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Why does SELLAS Life Sciences Group's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 6

Why is SELLAS Life Sciences Group's P/E ratio not available?

Accepted Answer

When trailing twelve-month earnings are negative (a net loss), the P/E ratio is mathematically meaningless and is reported as not available (N/A). In that case investors typically use P/S, EV/Sales, or forward P/E instead.


2025	$577M	-$26.9M	—	—	Dec 31, 2025
2024	$76.9M	-$30.9M	—	—	Dec 31, 2024
2023	$32.7M	-$37.3M	—	—	Dec 31, 2023
2022	$49.1M	-$41.3M	—	—	Dec 31, 2022
2021	$87.9M	-$20.7M	—	—	Dec 31, 2021
2020	$60.3M	-$16.8M	—	—	Dec 31, 2020
2019	$20.7M	-$19.3M	—	—	Dec 31, 2019
2018	$26.8M	-$27.7M	—	—	Dec 31, 2018
2017	$41.7M	-$34.4M	—	—	Dec 31, 2017
2016	$72.8M	-$23.5M	—	—	Dec 31, 2016
2015	$2.14B	-$63.9M	—	—	Dec 31, 2015
2014	$1.67B	-$36.6M	—	—	Dec 31, 2014
2013	$5.19B	-$76.7M	—	—	Dec 31, 2013
2012	$1.14B	-$35M	—	—	Dec 31, 2012
2011	$203M	-$11.5M	—	—	Dec 31, 2011
2010	$575M	-$12M	—	—	Dec 31, 2010
2009	$756M	-$18.4M	—	—	Dec 31, 2009
2008	$711M	-$14.4M	—	—	Dec 31, 2008
2007	$1.19B	-$11.6M	—	—	Dec 31, 2007


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Quest Diagnostics (DGX)	22.0×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
HCA Healthcare (HCA)	12.7×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for SELLAS Life Sciences Group (SLS)

P/E Ratio daily chart for SELLAS Life Sciences Group (SLS)

Historical P/E Ratio for SELLAS Life Sciences Group (SLS) from 2007 to 2025

About P/E Ratio at SELLAS Life Sciences Group (SLS)

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

SELLAS Life Sciences Group (SLS) Key Financials